Skip to main content
. 2010 Mar;12(3):275–283. doi: 10.1593/neo.91880

Figure 1.

Figure 1

Effect of ABT-510 on VEGF and VEGFR-2 levels. Serum and tumor tissue were collected from mice treated with vehicle (D5W) or ABT-510 and subjected to ELISA or Western blot analysis, respectively. (A) D5W-treated mice had increased circulating VEGF compared with non-tumor-bearing mice (control), whereas ABT-510 decreased VEGF levels compared with vehicle controls. (B) ABT-510 treatment at 60 days after tumor induction caused a decreased expression of VEGF protein in ovarian tumors. Bars with different letters are statistically different, and bars with asterisks are statistically different from D5W controls.